2 Unstoppable Growth Stocks That Could Double Your Money in 5 Years

Here’s a simple, two-step plan to double your capital in the next half-decade. First, invest in high-quality, high-growth stocks. Second, wait. Hold on to shares of these companies throughout this period, even amid market downturns.

The hardest part of this strategy might be the first, picking excellent companies. With hundreds of choices in the stock market, it’s not always easy to know where to look. That said, here are two excellent candidates to consider: Tandem Diabetes Care (NASDAQ:TNDM) and Shopify (NYSE:SHOP). 

TNDM data by YCharts.

1. Tandem Diabetes Care

Medical-device maker Tandem Diabetes Care is aiming to make a big difference in its namesake market. The company’s crown jewel is its t:slim X2, an innovative pump for the management of insulin-dependent diabetes. The t:slim X2 has seen continued growth in use because of its attractive qualities.

For one thing, it’s the smallest pump on the market, making it easier to conceal than those from competitors. In addition, its software can be updated remotely, which allows consumers to add new features as they become available. The t:slim X2 is the only insulin pump on the market with remote software-update capabilities. 

Here’s one more perk of this nifty device: It can be paired up with a continuous glucose monitoring (CGM) system — such as DexCom‘s G6 — to predict glucose levels in advance and deliver the amount of insulin needed automatically. This feature is linked to better health outcomes for diabetes patients.

The t:slim X2 helps make the lives of diabetics easier, and that’s why Tandem continues to record strong financial results. During the third quarter ended Sept. 30, the company recorded sales of $179.6 million from the t:slim X2 and accessories, representing a 45% year-over-year increase. And the company’s net income of $5.8 million during the quarter was a big improvement over the $9.4 million net loss it recorded in the third quarter of last year.

No doubt, more and more people are using these pumps. The company shipped 31,558 of them worldwide during the quarter, 43% higher than the year-ago period. And it ended the quarter with almost 300,000 installed bases of its crown jewel, having added more than 100,000 new customers in the trailing 12-month period.

Tandem has set a goal of reaching 500,000 installed bases by the end of 2024, and it looks well on its way to reaching that milestone. The U.S. market for insulin pumps suitable for type 1 diabetes patients (for whom insulin is a must) remains underpenetrated with roughly 65% of this patient population still relying on painful, multiple daily injections.

The t:slim X2 also appears to be doing well against the competition. According to the company, roughly half of its customers switched from another pump, which suggests that the t:slim X2 is very popular. Meanwhile, the market outside of the U.S. is even more untapped. What’s more, the number of…